Ulrika Andersson1, Carl Wibom1, Kristina Cederquist1, Steina Aradottir1, Ake Borg1, Georgina N Armstrong1, Sanjay Shete1, Ching C Lau1, Matthew N Bainbridge1, Elizabeth B Claus1, Jill Barnholtz-Sloan1, Rose Lai1, Dora Il'yasova1, Richard S Houlston1, Joellen Schildkraut1, Jonine L Bernstein1, Sara H Olson1, Robert B Jenkins1, Daniel H Lachance1, Margaret Wrensch1, Faith G Davis1, Ryan Merrell1, Christoffer Johansen1, Siegal Sadetzki1, Melissa L Bondy1, Beatrice S Melin1. 1. Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (U.A., C.W., B.S.M.); Computational Life Science Cluster (CLiC), Umeå University, Umeå, Sweden (C.W.); Department of Medical Biosciences, Pathology, Umeå University, Umeå Sweden (K.C.); Department of Oncology, Clinical Science, Lund University, Lund, Sweden (S.A., Å.B.); Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, Texas (G.N.A., M.L.B.); Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas (S.S.); Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas (C.C.L.); Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas (M.N.B.); School of Public Health, Yale University, New Haven, Connecticut (E.B.C.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (E.B.C.); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio (J.B.-S.); University of Southern California, Los Angeles, California (R.L.); Cancer Control and Prevention Program/Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina (D.I., J.S.); Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK (R.S.H.); Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center , New York, New York (J.L.B., S.H.O.); Mayo Comprehensive Clinic Cancer, Mayo Clinic, Rochester, Minnesota (R.B.J., D.H.L.); Department of Neurological Surgery, University of California, San Francisco, California (M.W.); School of Public Health, University of Alberta, Edmonton, Canada (F.G.D.); Department of Neurology, NorthShore University Health System, Evanston, Illinois (R.M.); Cancer Late Effects Research, Oncology, Finsencenteret, Rigshospitalet, University of Copenhagen and Head, Survivorship, Danish Cancer Society Research Center, Copenhagen, Denmark (C.J.)
Abstract
BACKGROUND: Although familial susceptibility to glioma is known, the genetic basis for this susceptibility remains unidentified in the majority of glioma-specific families. An alternative approach to identifying such genes is to examine cancer pedigrees, which include glioma as one of several cancer phenotypes, to determine whether common chromosomal modifications might account for the familial aggregation of glioma and other cancers. METHODS: Germline rearrangements in 146 glioma families (from the Gliogene Consortium; http://www.gliogene.org/) were examined using multiplex ligation-dependent probe amplification. These families all had at least 2 verified glioma cases and a third reported or verified glioma case in the same family or 2 glioma cases in the family with at least one family member affected with melanoma, colon, or breast cancer.The genomic areas covering TP53, CDKN2A, MLH1, and MSH2 were selected because these genes have been previously reported to be associated with cancer pedigrees known to include glioma. RESULTS: We detected a single structural rearrangement, a deletion of exons 1-6 in MSH2, in the proband of one family with 3 cases with glioma and one relative with colon cancer. CONCLUSIONS: Large deletions and duplications are rare events in familial glioma cases, even in families with a strong family history of cancers that may be involved in known cancer syndromes.
BACKGROUND: Although familial susceptibility to glioma is known, the genetic basis for this susceptibility remains unidentified in the majority of glioma-specific families. An alternative approach to identifying such genes is to examine cancer pedigrees, which include glioma as one of several cancer phenotypes, to determine whether common chromosomal modifications might account for the familial aggregation of glioma and other cancers. METHODS: Germline rearrangements in 146 glioma families (from the Gliogene Consortium; http://www.gliogene.org/) were examined using multiplex ligation-dependent probe amplification. These families all had at least 2 verified glioma cases and a third reported or verified glioma case in the same family or 2 glioma cases in the family with at least one family member affected with melanoma, colon, or breast cancer.The genomic areas covering TP53, CDKN2A, MLH1, and MSH2 were selected because these genes have been previously reported to be associated with cancer pedigrees known to include glioma. RESULTS: We detected a single structural rearrangement, a deletion of exons 1-6 in MSH2, in the proband of one family with 3 cases with glioma and one relative with colon cancer. CONCLUSIONS: Large deletions and duplications are rare events in familial glioma cases, even in families with a strong family history of cancers that may be involved in known cancer syndromes.
Authors: Siegal Sadetzki; Revital Bruchim; Bernice Oberman; Georgina N Armstrong; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Christoffer Johansen; Richard S Houlston; Sanjay Shete; Christopher I Amos; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel Lachance; Nicholas A Vick; Ryan Merrell; Margaret Wrensch; Faith G Davis; Bridget J McCarthy; Rose Lai; Beatrice S Melin; Melissa L Bondy Journal: Eur J Cancer Date: 2013-01-04 Impact factor: 9.162
Authors: D W Bell; J M Varley; T E Szydlo; D H Kang; D C Wahrer; K E Shannon; M Lubratovich; S J Verselis; K J Isselbacher; J F Fraumeni; J M Birch; F P Li; J E Garber; D A Haber Journal: Science Date: 1999-12-24 Impact factor: 47.728
Authors: P C Johannesma; H M van der Klift; N C T van Grieken; D Troost; H Te Riele; M A J M Jacobs; T J Postma; D A M Heideman; C M J Tops; J T Wijnen; F H Menko Journal: Clin Genet Date: 2011-02-20 Impact factor: 4.438
Authors: Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon Journal: Hum Mol Genet Date: 2011-04-29 Impact factor: 6.150
Authors: Preetha Rajaraman; Beatrice S Melin; Zhaoming Wang; Roberta McKean-Cowdin; Dominique S Michaud; Sophia S Wang; Melissa Bondy; Richard Houlston; Robert B Jenkins; Margaret Wrensch; Meredith Yeager; Anders Ahlbom; Demetrius Albanes; Ulrika Andersson; Laura E Beane Freeman; Julie E Buring; Mary Ann Butler; Melissa Braganza; Tania Carreon; Maria Feychting; Sarah J Fleming; Susan M Gapstur; J Michael Gaziano; Graham G Giles; Goran Hallmans; Roger Henriksson; Judith Hoffman-Bolton; Peter D Inskip; Christoffer Johansen; Cari M Kitahara; Mark Lathrop; Chenwei Liu; Loic Le Marchand; Martha S Linet; Stefan Lonn; Ulrike Peters; Mark P Purdue; Nathaniel Rothman; Avima M Ruder; Marc Sanson; Howard D Sesso; Gianluca Severi; Xiao-Ou Shu; Matthias Simon; Meir Stampfer; Victoria L Stevens; Kala Visvanathan; Emily White; Alicja Wolk; Anne Zeleniuch-Jacquotte; Wei Zheng; Paul Decker; Victor Enciso-Mora; Brooke Fridley; Yu-Tang Gao; Matthew Kosel; Daniel H Lachance; Ching Lau; Terri Rice; Anthony Swerdlow; Joseph L Wiemels; John K Wiencke; Sanjay Shete; Yong-Bing Xiang; Yuanyuan Xiao; Robert N Hoover; Joseph F Fraumeni; Nilanjan Chatterjee; Patricia Hartge; Stephen J Chanock Journal: Hum Genet Date: 2012-08-11 Impact factor: 4.132
Authors: Sanjay Shete; Fay J Hosking; Lindsay B Robertson; Sara E Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean-Yves Delattre; Khe Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu; Ching Lau; Minouk Schoemaker; Kenneth Muir; Anthony Swerdlow; Mark Lathrop; Melissa Bondy; Richard S Houlston Journal: Nat Genet Date: 2009-07-05 Impact factor: 38.330
Authors: Ekaterina Mostovenko; Ákos Végvári; Melinda Rezeli; Cheryl F Lichti; David Fenyö; Qianghu Wang; Frederick F Lang; Erik P Sulman; K Barbara Sahlin; György Marko-Varga; Carol L Nilsson Journal: ACS Chem Neurosci Date: 2017-12-21 Impact factor: 4.418
Authors: Ivo S Muskens; Mi Zhou; Lucie Mccoy; Paige M Bracci; Helen M Hansen; W James Gauderman; John K Wiencke; Margaret R Wrensch; Joseph L Wiemels Journal: Neurooncol Adv Date: 2019-09-29
Authors: Wendy Yi-Ying Wu; Gunnar Johansson; Carl Wibom; Thomas Brännström; Annika Malmström; Roger Henriksson; Irina Golovleva; Melissa L Bondy; Ulrika Andersson; Anna M Dahlin; Beatrice Melin Journal: Cancers (Basel) Date: 2019-12-12 Impact factor: 6.639
Authors: Sebastian Ribi; Daniel Baumhoer; Kristy Lee; Audrey S M Teo; Babita Madan; Kang Zhang; Wendy K Kohlmann; Fei Yao; Wah Heng Lee; Qiangze Hoi; Shaojiang Cai; Xing Yi Woo; Patrick Tan; Gernot Jundt; Jan Smida; Michaela Nathrath; Wing-Kin Sung; Joshua D Schiffman; David M Virshup; Axel M Hillmer Journal: Oncotarget Date: 2015-04-10